New pill takes on rare, stubborn lymphoma
NCT ID NCT06789159
First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times
Summary
This early-phase trial is testing an oral drug called VK-2019 in 30 adults with a type of lymphoma (DLBCL) that is linked to the Epstein-Barr virus and has not responded to at least two prior treatments. Participants take the drug daily in 28-day cycles at one of three dose levels to find the safest dose and see if it can control the cancer. The goal is to offer a new option for people who have run out of standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VK-2019 (an oral drug)
- What this could lead to
- If it works, this could point toward a new treatment option for people with a hard-to-treat type of lymphoma linked to the Epstein-Barr virus.
- What could go wrong
- This is an early Phase Ib trial with only 30 participants, so it is primarily testing safety and dosing. It may not show enough benefit to move forward, and side effects are unknown at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kentucky
RECRUITINGLexington, Kentucky, 40506, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a drug duo outsmart returning lymphoma?